B-1 cells promote immunosurveillance against murine melanoma in host absence of CCR5: New perspective in autologous vaccination therapy

Nenhuma Miniatura disponível
Vivanco, Bruno C. [UNIFESP]
Viana, Jacqueline D. [UNIFESP]
Perez, Elisabeth C.
Konno, Fabiana T. C.
Guereschi, Marcia G. [UNIFESP]
Xander, Patricia [UNIFESP]
Keller, Alexandre C. [UNIFESP]
Lopes, Jose D. [UNIFESP]
Título da Revista
ISSN da Revista
Título de Volume
Autologous vaccination with tumor-primed dendritic cells increases immune response against tumor, which seems to be improved in host absence of CCR5. Because B-1 lymphocytes modulate the activity of different immune cells, we decided to study their influence in the resistance against murine B16F10 melanoma in a CCR5 deprived environment. Adoptive transfer of peritoneal B-1 CCR5(+/+) lymphocytes to CCR5(-/-) animals inhibited the establishment of lung metastasis and melanoma cell growth, in comparison to saline-treated CCR5-/- mice. in loco cell analysis demonstrated that the adoptive transfer of B-1 CCR5(+/+) + lymphocytes to CCR5 deficient host was associated with a more intense influx of T CD8(+) to tumor site, indicating that the presence of CCR5(+/+) B-1 cells in the tumor environment induces the migration of T CD8 CCR5(-/-) cells to the implantation site. To corroborate this idea, CCR5(-/-) mice were injected with non B-1 peritoneal cells from wild type (WT) mice before B16F10 inoculation. in this regimen, CCR5(-/-) mice were not protected from tumor growth reinforcing the idea that, in host absence of CCR5, B-1 cells are essential to confer tumor resistance. This work indicates that, in the host absence of CCR5, naive B-1 cells may activate CD8T lymphocytes thereby promoting tumor resistance. Our results strongly suggest that autologous vaccination with B-1 lymphocytes in combination with CCR5 antagonists can be an alternative approach to tumor therapy. (C) 2014 Elsevier GmbH. All rights reserved.
Immunobiology. Jena: Elsevier Gmbh, Urban & Fischer Verlag, v. 219, n. 11, p. 845-849, 2014.